Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16341624 | 1.00 | CHRM1 (0.69) | CHRM1SMN1; SMN2LMNATHRBP2RX3 | |
| SCHEMBL22416277 | 0.92 | CHRM1 (0.58) | CHRM1SMN1; SMN2THRBP2RX3 | |
| SCHEMBL16340940 | 0.90 | CHRM1 (0.67) | CHRM1SMN1; SMN2LMNATHRBP2RX3 | |
| SCHEMBL16341390 | 0.88 | CHRM1 (0.66) | CHRM1SMN1; SMN2LMNAKLKB1 | |
| SCHEMBL16341587 | 0.88 | CHRM1 (0.74) | CHRM1SMN1; SMN2LMNATHRBPDE7A | |
| SCHEMBL16341768 | 0.86 | CHRM1 (0.72) | CHRM1SMN1; SMN2P2RX3 | |
| SCHEMBL16341521 | 0.86 | CHRM1 (0.72) | CHRM1SMN1; SMN2LMNAP2RX3KLKB1 | |
| SCHEMBL16341842 | 0.86 | CHRM1 (0.78) | CHRM1SMN1; SMN2LMNATHRB | |
| SCHEMBL16341306 | 0.84 | CHRM1 (0.69) | CHRM1SMN1; SMN2P2RX3 | |
| SCHEMBL16341833 | 0.84 | CHRM1 (0.69) | CHRM1SMN1; SMN2LMNATHRBKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2821401-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | Takeda Pharmaceutical Company Limited (JP) | 2015-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885SMN1; SMN2 2464/4885LMNA 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.